SCYNEXIS Acquires SCY-770 for Kidney Disease SCYNEXIS announced on Mar 31, 2026 the acquisition of SCY-770 for a rare kidney disease; regulatory incentives apply for populations under 200,000 in the U.S.

SCYNEXIS Acquires SCY-770 for Kidney Disease: SCYNEXIS announced on Mar 31, 2026 the acquisition of SCY-770 for a rare kidney disease; regulatory incentives apply for populations under 200,000 in the U.S. 👈 Read full analysis #SCYNEXIS #KidneyDisease #RareDisease #OrphanDrug #Pharmaceuticals

Exploring the Surge in Invasive Fungal Infections Market Growth Through 2034 The Invasive Fungal Infections market is on the rise, expecting significant growth at a CAGR of 11.4% from 2025 to 2034 in the U.S., driven by new therapies and rising incidence rates.

Exploring the Surge in Invasive Fungal Infections Market Growth Through 2034 #USA #Las_Vegas #GlaxoSmithKline #Invasive_Fungal_Infections #SCYNEXIS

SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines…...

SCYNEXIS will present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Austria being held from April 11-15, 2025. #SCYNEXIS

ir.scynexis.com/news-events/...